Skip to main content
. 2023 Oct 9;31(1):262–271. doi: 10.1245/s10434-023-14402-6

Table 1.

Clinicopathologic characteristics of patients

Characteristics No. of patients (%)
Sex
Male 200 (82.3)
Female 43 (17.7)
Median age: years (range) 63 (35–82)
Viral infection
HBV 90 (37.0)
HCV 92 (37.9)
HBV + HCV 8 (3.3)
NBNC 53 (21.8)
Child-Pugh class
A 237 (97.5)
B 6 (2.5)
Albumin (g/dl)
< 4 96 (39.5)
≥ 4 147 (60.5)
AFP (ng/ml)
≤ 10 127 (52.3)
> 10 114 (46.9)
PIVKAII (mAU/ml)
≤ 40 101 (43.2)
> 40 136 (56.0)
Differentiation
Well 40 (16.5)
Moderate 156 (64.2)
Poor 47 (19.3)
Tumor number
One 187 (77.0)
Multiple 56 (23.0)
Tumor size (cm)
≤ 2 36 (14.8)
> 2 to ≤5 129 (53.1)
> 5 to ≤10 59 (24.3)
> 10 19 (7.8)
Vascular invasion
Positive 39 (16.1)
Negative 204 (83.9)
Lymph node metastasis
Positive 0 (0.0)
Negative 243 (100.0)
pStagea
I 24 (9.9)
II 136 (56.0)
III 83 (34.2)
IVA 0 (0.0)
IVB 0 (0.0)
Non-cancerous liver
No cirrhosis 157 (64.6)
Cirrhosis 86 (35.4)
Wnt5a
Positive 63 (25.9)
Negative 180 (74.1)
ROR2
Positive 147 (60.5)
Negative 96 (39.5)

HBV hepatitis B virus, HCV hepatitis C virus, NBNC non-hepatitis B virus and non-hepatitis C virus, AFP α-fetoprotein, PIVKAII protein induced by vitamin K absence or antagonist II. Some categories did not include 243 patients because of incomplete data.

aLiver Cancer Study Group of Japan, 6th edition